The development of biotechnology has given access to novel peptides and proteins (NBEs) for treatment of various diseases. However, clinical trials of native NBEs have frequently resulted in limited success due to low efficacy or low duration of action due to either enzymatic degradation or high renal clearance of the NBEs. Another general challenge is drug product stability due to low chemical or physical stability or low aqueous solubility.Protein engineering has emerged as the technology used to optimize key properties of native NBEs to more stable and efficacious drugs with improved pharmaceutical profiles. The presentation will discuss these matters and exemplify how the interface of organic chemistry and protein chemistry can generate solutions to improve the pharmaceutical properties of peptides and proteins using glucagon like peptide 1 and insulin as case stories.

Pharmaceutical protein and peptide engineering

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.